Are we no longer a nation built upon risk?
September 1st 2005At a recent meeting of department directors, the president of my university, William Brody, MD, PhD, made an offhand comment that resonated with me. He noted that "the citizens of the United States, a nation built upon risk, seem no longer willing to accept any risk."
Surgical intervention beneficial to adult strabismus
September 1st 2005Orlando—A questionnaire administered to adults who underwent surgery for strabismus showed that most patients believed any disabilities related to this condition improved after the procedure, said George R. Beauchamp, MD, FACS, professor of clinical ophthalmology, University of Texas Southwestern Medical School, Dallas.
Visual complaints seen with neurodegenerative diseases
August 15th 2005St. Louis—Neurodegenerative diseases, such as Alzheimer's disease, Parkinson's disease, and progressive supranuclear palsy, are characterized by visual complaints, which must be assessed carefully to establish the correct diagnosis.
Intravitreal Sod2 injections able to rescue RGCs in mice
August 15th 2005Fort Lauderdale, FL—A potential new strategy has been proposed to treat optic neuritis and multiple sclerosis, namely, delivery of the superoxide dismutase (Sod) 2 gene. Intravitreal Sod2 injections in mice suppressed myelin fiber injury and rescued the retinal ganglion cells (RGCs) for up to 1 year after the inoculation, according to John Guy, MD.
Knowing services aspect key to marketing direction
August 15th 2005Understanding the fundamentals of services marketing is extremely useful for the optimal marketing of a medical practice. Basic knowledge in this area is also helpful when studying the marketing approach of your competitors. Additionally, you may consider these concepts when analyzing ads for which you are the targeted customer.
Liquefaction device is good alternative for cataract surgery
August 15th 2005Miami—Cataract surgeons performing standard ultrasound phacoemulsification will find the AquaLase liquefaction device (Alcon Laboratories) is an easy technique to transition to and is one that offers multiple advantages for enhancing the safety of lens removal, said Sonia H. Yoo, MD.
Sharp optic edge of IOL appears protective against PCO
August 15th 2005Frankfurt, Germany—The design of the optic edge seems to be one of the most important factors in the development of posterior capsule opacification (PCO). IOLs with a sharp edge have less PCO regardless of the lens material, according to Thomas Kohnen, MD.
Novel causative gene identified for adult-onset POAG
August 15th 2005Fort Lauderdale, FL—WDR36 is a novel causative gene for adult-onset primary open-angle glaucoma (POAG) that is located at the GLC1G locus. Sharareh Monemi, MD, PhD, and Mansoor Sarfarazi, PhD, explained that this discovery should help in the diagnosis and treatment of glaucoma.
Fluoroquinolone provides superior broad pathogen coverage
August 15th 2005Fort Lauderdale, FL—The results from a clinical trial demonstrate that topical moxifloxacin 0.5% ophthalmic solution (Viga-mox, Alcon Laboratories) instilled in a q.i.d. dosing regimen achieves a significantly higher concentration in aqueous humor compared with topical gatifloxacin 0.3% ophthalmic solution (Zymar, Allergan) to provide antibacterial coverage for a broader range of important ocular pathogens, said Joel D. Aronowicz, MD, at the annual meeting of the Association for Research in Vision and Ophthalmology.
Fluoroquinolones compared in corneal healing
August 15th 2005Fort Lauderdale, FL—Results from a preclinical study indicate that fluoroquinolones available for ophthalmic use may differ in their effects on corneal healing, said Luis E. Fern?ndez de Castro, MD, at the annual meeting of the Association for Research in Vision and Ophthalmology.
PDT may be ideal for treating circumscribed choroidal hemangioma
August 15th 2005Cleveland—Verteporfin photodynamic therapy (Visudyne PDT, Novartis Ophthal-mics/QLT Inc.) for symptomatic circumscribed choroidal hemangioma appears to be safe, effective, and associated with potential benefits relative to alternative modalities, said Arun D. Singh, MD.
AMD research takes aim at choroidal neovascularization
August 15th 2005Los Angeles—The medical management of age-related macular generation (AMD) has progressed by leaps and bounds in a very short space of time and generated a great deal of excitement among retina specialists. In particular, translational research has resulted in a large number of drugs that target choroidal neovascularization (CNV).